Bavarian Nordic eyes more U.S. government contracts Following new vaccine order
The deal was a significant confidence boost for the firm, just weeks after one of its key drug candidates suffered a significant setback.”We are expecting that they (the U.S. Biomedical Advanced Research and Development Authority (BARDA)) have a desire to expand the emergency stock for the smallpox vaccine and therefore we also expect to see more contracts in the future,” Chief Financial Officer Ole Larsen told Reuters.
Reporting by Stine Jacobsen, editing by Terje Solsvik
The biotech said late on Wednesday it had won an order for its smallpox vaccine worth possibly $539 million.
Published at Thu, 28 Sep 2017 09:48:38 +0000
COPENHAGEN (Reuters) – Danish drug maker Bavarian Nordic expects to acquire further U.S. contracts because of its smallpox vaccine after it secured a crucial government arrangement, the company said on Thursday.